Bolt Biotherapeutics to Participate in Upcoming Conferences

The October reverse merger brought Prana’s pipeline to Bolt alongside $120 million in private placement financing.

Rhea-AI Summary

Bolt Biotherapeutics (BOLT) will participate in two investor conferences, with its Stifel presentation scheduled for November 10, 2026.

Chief Strategy Officer Sheila Gujrathi will present and join a fireside chat at 10:40 a.m. ET, and attend the Jefferies Global Healthcare Conference in London on November 16–19. In October 2026, Bolt acquired Prana Therapies through a stock-for-stock reverse merger alongside $120 million in private placement financing. Accompanying warrants could provide up to an additional $60 million upon exercise. Bolt is now primarily focused on advancing Prana’s antibody pipeline, led by PRA-216, currently in Phase 2 development across multiple inflammatory diseases.

3 points · 2 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointPrivate placement financing provided $120 million alongside the October 2026 acquisition. 8.2× market cap
• Major pointPrana Therapies acquisition completed through a stock-for-stock reverse merger in October 2026.
• Minor pointPipeline advancement is now Bolt’s primary focus, led by PRA-216 in Phase 2 across multiple inflammatory diseases.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Additional financing of up to $60 million depends on exercise of accompanying warrants. 4.1× market cap

Key Terms

multispecific antibodies, reverse merger, private placement

3 terms

multispecific antibodies technical

"half-life-extended multispecific antibodies designed to deliver best-in-disease therapies"

Multispecific antibodies are engineered immune proteins designed to bind two or more different targets at the same time, like a multitool that can grab several distinct screws in one go. For investors, they matter because combining multiple actions in a single drug can improve effectiveness, reduce side effects, or replace combination therapies, which can speed development, broaden potential markets, and affect a drug candidate’s commercial and regulatory prospects.

reverse merger financial

"acquired Prana Therapies in a stock-for-stock reverse merger"

A reverse merger is when a private company becomes publicly traded by combining with an already listed public shell company, allowing the private business to gain a stock market listing without going through a traditional IPO. Investors care because this shortcut can be faster and cheaper than an IPO but often comes with less regulatory vetting and market visibility, so it can mean higher uncertainty about valuation, financial transparency, and future liquidity.

private placement financial

"alongside a $120 million private placement financing"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced participation in two upcoming investor conferences. 

Sheila Gujrathi, M.D., Chief Strategy Officer of Bolt and Co-Founder and former Chief Executive Officer of Prana Therapies, will deliver a company presentation, followed by a fireside chat, on Tuesday, November 10, 2026, at 10:40 a.m. ET at the Stifel 2026 Healthcare Conference, and attend Jefferies Global Healthcare Conference in London, taking place November 16–19, 2026.

In October 2026, Bolt acquired Prana Therapies in a stock-for-stock reverse merger alongside a $120 million private placement financing, with the potential for up to an additional $60 million upon exercise of accompanying warrants. Following the acquisition, Bolt is primarily focused on advancing Prana’s pipeline of next-generation, half-life-extended multispecific antibodies, led by PRA-216, which is currently in Phase 2 development across multiple inflammatory diseases.

Members of the management team will host one-on-one investor meetings during the conferences. A live webcast of the Stifel presentation will be available on the Events and Presentations section of Bolt’s website at https://investors.boltbio.com/news-and-events/events-and-presentations, with an archived replay accessible following the event date.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics is a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Through the proprietary INSPIRE platform it acquired from Prana Therapies, the company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for differentiated efficacy, extended exposure, and convenient dosing.

The company’s lead program, PRA-216, is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase 2 study planned in eosinophilic esophagitis. In addition to PRA-216, Bolt Biotherapeutics is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need.

Bolt’s pipeline also includes BDC-4182, a claudin 18.2-targeting Boltbody™ ISAC.

For more information, please visit https://www.boltbio.com/.

Forward-Looking Statements

This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including, without limitation, statements regarding Bolt, Prana, the concurrent private placement financing and the acquisition of Prana by Bolt (the “Transactions”) and other matters, including, without limitation, statements regarding: any additional gross proceeds that may be received upon exercise, if any, of accompanying warrants, if any, in the Transactions and the expected effects, perceived benefits or opportunities and related timing with respect thereto; expectations regarding or plans for the company’s pipeline, including its ongoing and planned clinical trials, research and development programs and the expected timing for key milestones, including the release of clinical data; the potential benefits of PRA-216 and Prana’s other clinical programs; and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the company’s ability to consummate the private placement financing or realize the anticipated benefits from the transactions, including as a result of its failure to receive the requisite stockholder approvals; investors in the private placement may not exercise their warrants and the company may not receive any additional proceeds therefrom; the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.

Contacts

Christina Trout
VP, Corporate Development
investors@pranatherapies.com
(650) 665-9295

Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much financing accompanied Bolt Biotherapeutics’ acquisition of Prana Therapies?

Bolt’s October 2026 acquisition of Prana Therapies was accompanied by $120 million in private placement financing. Accompanying warrants have the potential to provide up to an additional $60 million upon exercise.